Charles Goodwin, MD
Urology · Jeffersonville, INNPI 1710001607
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Medtronic at 52.1% of the total.
Across 251 payments — averaging $33.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Teleflex LLC$771
- Endo Pharmaceuticals Inc.$743
- Sumitomo Pharma America, Inc.$376
- Astellas Pharma US Inc$212
- Merck$197
- plus $2K from 29 others
Across 2 payments — averaging $1184.27 each. An ownership or investment interest held by the physician or an immediate family member.
- Louisville URS Solutions, LLC$2K
What the payments were for
- Food & beverage$8,34599%
- Education$1051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 99 | $4,405 |
| Teleflex LLC | 9 | $771 |
| Endo Pharmaceuticals Inc. | 34 | $743 |
| Sumitomo Pharma America, Inc. | 21 | $376 |
| Astellas Pharma US Inc | 9 | $212 |
| Merck | 6 | $197 |
| Accord Healthcare, Inc. | 5 | $178 |
| Palette Life Sciences, Inc. | 1 | $173 |
| AbbVie(2 entities) | 9 | $170 |
| Boston Scientific | 5 | $123 |
| Amgen | 7 | $115 |
| Johnson & Johnson | 6 | $99 |
| Blue Earth Diagnostics | 1 | $92 |
| Bioprotect Medical, Inc. | 3 | $76 |
| Zyla Life Sciences, Inc. | 6 | $76 |
| Laborie Medical Technologies Corp. | 1 | $76 |
| Urogen Pharma, Inc. | 3 | $74 |
| Novartis | 3 | $57 |
| Urovant Sciences Inc | 3 | $56 |
| Endo USA, Inc. | 2 | $41 |
| Halozyme Inc | 2 | $40 |
| Siemens Medical Solutions USA, Inc. | 1 | $39 |
| Calyxo, Inc. | 1 | $32 |
| Antares Pharma, Inc. | 2 | $29 |
| Immunitybio, Inc. | 2 | $29 |
| Myovant Sciences Inc. | 1 | $22 |
| Coloplast | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Travere Therapeutics, Inc. | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Neotract Inc. | 1 | $15 |
| Vertex | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,219
- UroLift System$635
- ALTAVIVA$269
- CAMCEVI$107
- KEYTRUDA$106
How this compares
$8,449 in reported general payments places this provider in the 70th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 369 | $297,912 |
| MyrbetriqMirabegron | 295 | $283,024 |
| Tamsulosin Hcl | 1,287 | $16,559 |
| Testosterone | 50 | $14,231 |
| Trimethoprim | 167 | $13,345 |
| Mirabegron ErMirabegron | 14 | $10,107 |
| Finasteride | 350 | $4,166 |
| Solifenacin Succinate | 41 | $3,611 |
| Oxybutynin Chloride ErOxybutynin Chloride | 72 | $2,515 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 17 | $2,245 |
| Cephalexin | 244 | $1,722 |
| Testosterone Cypionate | 38 | $1,695 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $1,514 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 105 | $1,394 |
| Desmopressin Acetate | 18 | $1,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $376 | $297,912369 claims |
| Astellas Pharma US IncMyrbetriq | $212 | $283,024295 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 272 urology providers in Indiana.
Other urology in Jeffersonville
- James BailenJeffersonville$143K
- Greg SteinbockJeffersonville$134K
- Ryan MaloneJeffersonville$97K
- William SchmiedJeffersonville$58K
- Barry PechaJeffersonville$50K
- David RosenbaumJeffersonville$39K
- John EiflerJeffersonville$26K
- Ganesh RaoJeffersonville$19K
- Bradley BellJeffersonville$16K
- Aaron BeckerJeffersonville$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.